Skip to content

Lung squamous cell carcinoma — molecular landscape

TL;DR — TCGA’s 178-tumor analysis defined LUSC as a high-complexity, smoking-scarred genome: a mean 360 coding mutations, 165 rearrangements, and 323 copy-number segments per tumor, with TP53 altered in nearly all samples (TCGA 2012, PMID 22960745). Pathway-level alteration was more informative than any single driver: CDKN2A/RB1 in 72%, PI3K-pathway genes in 47%, squamous-differentiation genes in 44%, and NFE2L2/KEAP1 in 34% (TCGA 2012, PMID 22960745). This is a landscape of tumor-suppressor loss, copy-number gain, oxidative-stress adaptation, and lineage programs rather than the recurrent oncogene addictions that transformed adenocarcinoma care. FGFR1 amplification (22% in an early validation cohort) and DDR2 mutation (~4%) produced compelling preclinical dependencies but failed to yield a LUSC-specific approved therapy, showing that alteration prevalence is not clinical actionability (Weiss 2010, PMID 21160078; Hammerman 2011, PMID 22328973). Proteogenomic and single-cell studies now divide tumors into inflamed, redox, epithelial, and stromal states, but these taxonomies remain research tools rather than validated treatment selectors (Stewart 2019, PMID 31395880; Wang 2022, PMID 36008393).

The TCGA baseline

TCGA integrated exome sequencing, copy number, mRNA, microRNA, methylation, and proteomic data. Its key result was not simply a gene list; it was the coexistence of multiple altered pathways in almost every tumor (TCGA 2012, PMID 22960745).

Feature TCGA estimate Biological consequence Translational state
Mean exonic mutations 360/tumor High neoantigen potential and passenger burden TMB is not a stand-alone LUSC selector
Mean genomic rearrangements 165/tumor Structural complexity Most rearrangements are not recurrent drug targets
Mean copy-number segments 323/tumor Aneuploidy/amplification/deletion Copy gain often fails to prove dependency
TP53 mutation Nearly universal Genome surveillance loss No established TP53-directed standard
CDKN2A/RB1 pathway 72% Cell-cycle checkpoint disruption CDK4/6 matching failed in Lung-MAP
PI3K pathway 47% Growth/metabolic signaling PI3K inhibitor matching failed in Lung-MAP
Squamous differentiation 44% Lineage maintenance/plasticity Targeting lineage factors remains preclinical
NFE2L2/KEAP1 pathway 34% Oxidative-stress defense Resistance marker and emerging vulnerability

These percentages describe pathway alterations, not mutually exclusive subgroups; one tumor can enter several rows. A claimed “potential target” in genomic annotation is also not equivalent to an approved matched therapy (TCGA 2012, PMID 22960745).

Recurrent genes and copy-number events

Gene/locus Alteration type Approximate role in LUSC Evidence boundary
TP53 Mutation/deletion Genome integrity; founder/early event Near-universal but not directly druggable; TCGA 2012, PMID 22960745
CDKN2A Deletion, mutation, methylation Removes p16/p14 cell-cycle control Palbociclib matching did not translate; TCGA 2012, PMID 22960745
RB1 Loss/mutation G1/S checkpoint May cooperate with lineage plasticity
SOX2 3q amplification Squamous lineage and stemness Amplified progressively in high-grade precursors; McCaughan 2010, PMID 20299530
TP63 3q amplification/ΔNp63 program Basal/squamous survival program Transcription factor without validated drug
PIK3CA Mutation/amplification PI3K–AKT–mTOR signaling Alteration ≠ response to taselisib
NFE2L2 Hotspot mutation Constitutive NRF2 activity Enriched in LUSC; oxidative/therapy resistance
KEAP1 Loss-of-function Releases NRF2 Histology and co-mutation dependent
FGFR1 8p amplification/rearrangement Receptor-tyrosine-kinase signaling Amplification is an imprecise dependency marker
DDR2 Kinase mutation Collagen-receptor signaling ~3.8% discovery prevalence; dasatinib toxicity/resistance
NOTCH1/2 Loss-of-function Differentiation control Tumor-suppressor pattern limits direct inhibition
FAT1 Mutation Adhesion/Hippo pathway Common but not validated therapeutically
HLA-A/B2M-related events Loss/mutation Antigen presentation/immune escape Candidate IO-resistance mechanisms

The 3q amplicon illustrates temporal continuity: in 19 bronchial precursor biopsies, all high-grade and no low-grade lesions had 3q amplification, with SOX2 and PIK3CA in the shared region; 8 of 10 patients with high-grade disease progressed (McCaughan 2010, PMID 20299530). The finding is biologically coherent but numerically small.

FGFR1: the archetypal amplification trap

Weiss et al. screened 232 lung tumors and confirmed focal FGFR1 amplification in 22% of an independent LUSC cohort. Amplified cell lines underwent growth inhibition/apoptosis with FGFR blockade, and xenografts shrank (Weiss 2010, PMID 21160078).

Subsequent meta-analysis found prevalence sensitive to assay and cutoff, underscoring that “amplified” is not a standardized biological state (Jiang 2015, PMID 25433983). Copy number may mark a broad 8p amplicon, while ligand abundance, transcript/protein expression, co-drivers, and intratumoral heterogeneity determine actual FGFR dependence (Weeden 2015, PMID 27551478).

Somatic FGFR1 rearrangements producing oncogenic ectodomain deletions provide a mechanistically sharper alteration than bulk amplification, but their rarity makes prospective matching difficult (Malchers 2023, PMID 37606995). Clinical failures are detailed in failed and frontier targets.

DDR2: mutation is not enough

Kinome sequencing found DDR2 mutations in 3.8% of LUSCs/cell lines; mutant models were sensitive to DDR2 knockdown and dasatinib, and one responding patient had a kinase-domain mutation (Hammerman 2011, PMID 22328973). Later work identified resistance through a DDR2 gatekeeper mutation and NF1 loss, illustrating both on-target and bypass resistance (Beauchamp 2014, PMID 24296828).

The rapid-translation narrative was weakened by low prevalence, heterogeneous mutation function, and dasatinib tolerability. “DDR2-mutant” combines variants with different oncogenicity, so a mutation label without functional classification dilutes trial signal.

NRF2–KEAP1 redox biology

KEAP1 restrains NRF2 under basal conditions. Loss of KEAP1 or activating NFE2L2 mutation drives antioxidant, glutathione, detoxification, and metabolic programs that protect tumor cells from oxidative stress.

Evidence layer Finding Interpretation
TCGA NFE2L2/KEAP1 pathway altered in 34% Core LUSC pathway; TCGA 2012, PMID 22960745
IHC cohort, 304 NSCLC Nuclear NRF2 in 38% of LUSC vs 18% adenocarcinoma Protein activation exceeds mutation prevalence; Solis 2010, PMID 20534738
Same cohort Low/absent KEAP1 in 46% of LUSC; HR 2.09 for OS Retrospective prognostic association; Solis 2010, PMID 20534738
Trp53/Keap1 mouse model Basal-cell tumors with aggression, metastasis, and radioresistance Mechanistic evidence; Jeong 2017, PMID 27663899
1,391 clinical NSCLC KEAP1 11.3%, NFE2L2 3.5%; no KEAP1 cases responded to systemic therapy in observed lines Heterogeneous histologies/treatments; Frank 2018, PMID 29615460
Lung-MAP, 1,672 advanced LUSC NFE2L2/KEAP1 jointly associated with poorer survival Largest trial-linked LUSC genomic cohort; Kozono 2024, PMID 39111731

The clinical datasets make NRF2/KEAP1 a credible adverse state, but prognostic and predictive effects remain difficult to separate. Treatment nonresponse in small molecular subgroups should not be interpreted as proof that every KEAP1/NFE2L2 tumor resists every therapy (Frank 2018, PMID 29615460).

Cell cycle and PI3K: frequent pathway, weak selector

CDKN2A/RB1 and PI3K alterations are frequent at pathway level, but individual lesions vary: deletion, mutation, amplification, methylation, and protein loss need not confer the same drug sensitivity (TCGA 2012, PMID 22960745).

In Lung-MAP, palbociclib in cell-cycle-altered LUSC and taselisib in PI3K-positive LUSC did not establish practice-changing activity (Edelman 2019, PMID 31302234; Langer 2019, PMID 31158500). These results argue that broad pathway eligibility can be too permissive, not that the pathways are biologically irrelevant.

Proteogenomic states

The proteogenomic study of 108 LUSCs integrated DNA copy number, mutation, RNA, and protein expression and found three proteomic subtypes. Inflamed and Redox comprised 87% of tumors (Stewart 2019, PMID 31395880).

Proteomic state Features Candidate implication Caveat
Inflamed Neutrophils, B cells, monocytes; higher PD-1 Immune-directed therapy or tertiary-lymphoid-structure biology Subtype itself did not predict survival
Redox Oxidation-reduction/glutathione pathways; NFE2L2/KEAP1; 3q2 gain Metabolic vulnerabilities (TP63, PSAT1, TFRC) No validated matched clinical intervention
Third/smaller state Distinct protein-expression pattern Hypothesis-generating Small subgroup and assay complexity
B-cell-rich tertiary lymphoid structures More frequent in Inflamed Associated with better survival Observational within one cohort

Proteins are closer to functional state than DNA, but fresh-frozen tissue, batch normalization, and platform requirements limit clinical portability. The absence of a subtype-survival association warns against overinterpreting molecular elegance (Stewart 2019, PMID 31395880).

Transcriptomic and pan-squamous context

Pan-squamous analysis across five anatomical sites found shared 3q/5p copy changes, ΔNp63 promoter activation, lineage/stemness programs, and co-expression of checkpoint, regulatory-T-cell, and myeloid-suppressor signatures (Campbell 2018, PMID 29617660). These similarities may enable histology-spanning trials, but organ site, viral etiology, exposure, and microenvironment remain consequential.

Gene-expression subtypes of LUSC show different immune landscapes and survival associations, yet classifiers vary across datasets and are not interchangeable (Faruki 2017, PMID 28341226). A robust clinical subtype would need locked assay, reproducibility, prospective treatment interaction, and utility beyond PD-L1/stage.

Single-cell ecosystem

Cell compartment LUSC observation Source
Malignant basal-like cells Amplification and transcriptional modules distinct from AT2-like adenocarcinoma cells Zhang 2022, PMID 35027529
Macrophages SPP1-positive macrophages dominant in LUSC versus FABP4-positive macrophages in adenocarcinoma Wang 2022, PMID 36008393
Cytotoxic T/NK cells Composition and state differ by histology Wang 2022, PMID 36008393
Fibroblast/endothelial compartments Heterogeneous stromal programs Early atlases; clinical targeting unvalidated

The Wang atlas contained 72,475 immune cells from 40 tumor/adjacent samples in 19 patients. Cell number is large, but the independent-patient denominator is small; pseudoreplication must not inflate certainty (Wang 2022, PMID 36008393).

Heterogeneity and evolution

Multiregion TRACERx analysis showed branched evolution and ctDNA shedding in early NSCLC, establishing that a single biopsy incompletely represents a tumor (Abbosh 2017, PMID 28445469). LUSC’s high mutation and copy-number burden compounds spatial heterogeneity.

Radiogenomic profiling linked imaging phenotypes to LUSC genomic programs, but associations require external validation before image features can substitute for tissue (Abazeed 2013, PMID 23980093). Field carcinogenesis adds a second scale of heterogeneity: separate airway lesions can be clonally related or independent (Pipinikas 2014, PMID 24550057).

How often does sequencing find something actionable?

“Actionable” depends on whether it means approved drug, off-label evidence, trial eligibility, or biological plausibility.

Cohort Finding Actionability definition
130 evaluable real-world LUSCs 38% had alteration qualifying for Lung-MAP, another trial, or approved therapy; 24% of submitted samples insufficient Broad trial/diagnostic definition; Sands 2020, PMID 31855703
Same cohort 47% light/never vs 35% moderate/heavy smokers Enrichment, not proof of treatment benefit
Same cohort Alternative diagnosis suggested in 7 patients; 35% of light/never smokers Sequencing as diagnostic quality control
Japanese LUSC/adenosquamous, n=129 40% any assayed alteration; PIK3CA mutation 13%, copy gain 15%, EGFR mutation 6% Limited multi-assay panel; Kenmotsu 2014, PMID 25348872
GENIE NSCLC, n=8,675 5% of LUSC had alterations in eight genes with approved NSCLC targets Narrower approved-target definition; Adib 2022, PMID 35428358

The 5% and 38% estimates are not contradictory: the former uses eight established target genes, while the latter includes research-trial pathways and diagnostic findings (Sands 2020, PMID 31855703; Adib 2022, PMID 35428358).

Molecular testing as diagnostic safeguard

In the Sands cohort, NGS suggested metastatic cutaneous SCC or mesothelioma in seven cases. A “LUSC” arising in a never-smoker, with atypical imaging or unusual genomic pattern, deserves renewed pathology and clinical review rather than automatic enrollment in a squamous algorithm (Sands 2020, PMID 31855703).

Prospective Japanese profiling found more alterations in snap-frozen than formalin-fixed tissue (50% vs 29%), demonstrating that assay yield is partly preanalytic (Kenmotsu 2014, PMID 25348872). Negative testing is meaningful only after assessing tumor fraction, breadth, DNA/RNA quality, and fusion coverage.

Open questions

  • Which genomic alterations are true clonal dependencies rather than passengers within amplified segments (Weiss 2010, PMID 21160078; TCGA 2012, PMID 22960745)?
  • Can NRF2/KEAP1 status prospectively select a redox-directed therapy or modified radiation strategy (Jeong 2017, PMID 27663899; Kozono 2024, PMID 39111731)?
  • Do proteomic Inflamed/Redox states predict treatment interaction after adjustment for PD-L1, stage, and smoking (Stewart 2019, PMID 31395880)?
  • How should trial designs distinguish functionally validated DDR2/PIK3CA/FGFR events from broad pathway positivity (Hammerman 2011, PMID 22328973)?
  • Can single-cell ecosystem markers be reduced to a reproducible clinical assay without losing spatial information (Wang 2022, PMID 36008393)?

References

  1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25. PMID 22960745
  2. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93. PMID 21160078
  3. Jiang T, Gao G, Fan G, Li M, Zhou C. FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. Lung Cancer. 2015;87(1):1-7. PMID 25433983
  4. Weeden CE, Solomon B, Asselin-Labat ML. FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Discov. 2015;1:15049. PMID 27551478
  5. Malchers F, Nogova L, van Attekum MH, Maas L, Brägelmann J, Bartenhagen C, et al. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer. J Clin Invest. 2023;133(21). PMID 37606995
  6. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011;1(1):78-89. PMID 22328973
  7. Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, et al. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther. 2014;13(2):475-82. PMID 24296828
  8. McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med. 2010;182(1):83-91. PMID 20299530
  9. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010;16(14):3743-53. PMID 20534738
  10. Jeong Y, Hoang NT, Lovejoy A, Stehr H, Newman AM, Gentles AJ, et al. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discov. 2017;7(1):86-101. PMID 27663899
  11. Frank R, Scheffler M, Merkelbach-Bruse S, Ihle MA, Kron A, Rauer M, et al. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clin Cancer Res. 2018;24(13):3087-3096. PMID 29615460
  12. Kozono D, Hua X, Wu MC, Tolba KA, Waqar SN, Dragnev KH, et al. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). J Thorac Oncol. 2024;19(12):1618-1629. PMID 39111731
  13. Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, et al. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019;14(10):1853-1859. PMID 31302234
  14. Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, et al. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019;14(10):1839-1846. PMID 31158500
  15. Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, et al. Proteogenomic landscape of squamous cell lung cancer. Nat Commun. 2019;10(1):3578. PMID 31395880
  16. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, et al. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018;23(1):194-212.e6. PMID 29617660
  17. Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. J Thorac Oncol. 2017;12(6):943-953. PMID 28341226
  18. Wang C, Yu Q, Song T, Wang Z, Song L, Yang Y, et al. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal Transduct Target Ther. 2022;7(1):289. PMID 36008393
  19. Zhang L, Zhang Y, Wang C, Yang Y, Ni Y, Wang Z, et al. Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer. Signal Transduct Target Ther. 2022;7(1):9. PMID 35027529
  20. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. PMID 28445469
  21. Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73(20):6289-98. PMID 23980093
  22. Pipinikas CP, Kiropoulos TS, Teixeira VH, Brown JM, Varanou A, Falzon M, et al. Cell migration leads to spatially distinct but clonally related airway cancer precursors. Thorax. 2014;69(6):548-57. PMID 24550057
  23. Sands JM, Nguyen T, Shivdasani P, Sacher AG, Cheng ML, Alden RS, et al. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer. 2020;140:35-41. PMID 31855703
  24. Kenmotsu H, Serizawa M, Koh Y, Isaka M, Takahashi T, Taira T, et al. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. BMC Cancer. 2014;14:786. PMID 25348872
  25. Adib E, Nassar AH, Abou Alaiwi S, Groha S, Akl EW, Sholl LM, et al. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Med. 2022;14(1):39. PMID 35428358